

---

# Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana

Sylvia K. Ofori, Jessica S. Schwind, Kelly L. Sullivan,  
Gerardo Chowell, Benjamin J. Cowling, Isaac Chun-Hai Fung

We assessed the effect of various COVID-19 vaccination strategies on health outcomes in Ghana by using an age-stratified compartmental model. We stratified the population into 3 age groups: <25 years, 25–64 years, and ≥65 years. We explored 5 vaccination optimization scenarios using 2 contact matrices, assuming that 1 million persons could be vaccinated in either 3 or 6 months. We assessed these vaccine optimization strategies for the initial strain, followed by a sensitivity analysis for the Delta variant. We found that vaccinating persons <25 years of age was associated with the lowest cumulative infections for the main matrix, for both the initial strain and the Delta variant. Prioritizing the elderly (≥65 years of age) was associated with the lowest cumulative deaths for both strains in all scenarios. The consensus between the findings of both contact matrices depended on the vaccine rollout period and the objective of the vaccination program.

Ghana reported its first case of COVID-19 on March 12, 2020, and 171,065 cases and 1,445 deaths had been recorded as of December 31, 2022 (1). The country introduced various public health measures when the pandemic first emerged, including school closures, travel bans, mask mandates, and, later, vaccination, all of which were associated

with a decline in transmission (2). Ghana was the first country to receive 600,000 doses of the Oxford-AstraZeneca COVID-19 AZD1222 vaccine (<https://www.astrazeneca.com>) on February 24, 2021, through the COVAX program (3). The vaccination program was deployed in March 2021; politicians and civil society leaders publicly received vaccines to boost nationwide trust in the program (4). The first batch of vaccines was delivered to regions and populations with the highest burden of COVID-19: the Greater Accra and Ashanti regions, frontline healthcare workers, the elderly, and persons with comorbidities. In addition to the initially dispersed vaccine doses, the Ministry of Health received an additional supply of the AZD1222 vaccine and the Pfizer-BioNTech BNT162b2 vaccine (<https://www.pfizer.com>) from several high-income countries (5).

Given the limited availability of doses and vaccine hesitancy, only 9.2% of the Ghana population of 30,800,000 was fully vaccinated as of December 2021 (6). Hence, the government's goal to reach widespread vaccine coverage by October 2021 was not met (3). Studies of COVID-19 vaccine hesitancy among residents of Ghana reported that >35% of study participants said they would not receive the vaccine because of concerns about vaccine efficacy and conspiracy theories (4,7). Moreover, a seroprevalence study in August 2020 found that only 19% of Ghana residents tested positive for SARS-CoV-2 IgM, IgG, or both (8). Such studies suggest that most of the population in Ghana remains susceptible to SARS-CoV-2, and mitigating the pandemic might best be achieved through effectively prioritizing the dispensation of limited vaccines. To optimize Ghana's vaccination strategy, provide evidence of the benefits of vaccination, and increase uptake in the population, research is required to quantify the vaccine's effect on the magnitude of the epidemic peak, cumulative infections,

---

Author affiliations: Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (S.K. Ofori); Georgia Southern University Jiann-Ping Hsu College of Public Health, Statesboro, Georgia, USA (S.K. Ofori, K.L. Sullivan, I.C.-H. Fung); Georgia Southern University Institute for Health Logistics and Analytics, Statesboro (J.S. Schwind); Georgia State University School of Public Health, Atlanta, Georgia, USA (G. Chowell); WHO Collaborating Centre for Infectious Disease Epidemiology and Control, The University of Hong Kong School of Public Health, Pokfulam, Hong Kong (B.J. Cowling)

DOI: <http://doi.org/10.3201/eid2902.221098>

and deaths in the context of limited vaccine supplies and logistical barriers.

Several mathematical modeling studies of COVID-19 vaccination strategies in other countries and jurisdictions were published in 2020 and 2021 (9–13). Alagoz et al. used an agent-based model to simulate the transmission dynamics of COVID-19, accounting for the proportion of the population vaccinated, vaccine capacity, and adherence to nonpharmaceutical interventions (9). Moghadas et al. used an agent-based model to evaluate the effect of vaccination campaigns on reducing incidence, hospitalizations, and deaths (10). Aside from agent-based models, homogenous-mixing and age-stratified compartmental models also have been used. Matrajt et al. used an age-stratified deterministic model, paired with optimization algorithms, for 16 age groups by varying vaccination efficacy and coverages in the population (11). Mumtaz et al. used an age-stratified model to assess the vaccination rollout under different vaccination coverages accounting for the decline in transmission and age-mixing matrix (12). Bubar et al. expanded their work further to account for contact structure, seroprevalence, and age-specific vaccine efficacy (13). The outcomes explored in these studies included symptomatic infections, cumulative infections and deaths, and hospitalizations, focusing mainly on high-income countries outside Africa. Thus, determining who to vaccinate first when vaccines are available and analyzing the sensitivity of modeling outputs to the choice of contact matrices are underexplored in the Africa context and in Ghana specifically.

We employed an age-stratified model to assess the effect of vaccinating 1 million persons in 3 versus 6 months using 2 Africa contact matrices. We retrospectively assessed the counterfactual effect of various age-targeted vaccine optimization strategies against the initial and Delta strains of SARS-CoV-2 when vaccines first became available. Our aim was to inform future vaccination programs by identifying factors critical to achieving optimal outcomes. The Georgia Southern University Institutional Review Board determined that this project (H20364) was exempt from full review under the nonhuman subjects determination (G8) according to the Code of Federal Regulations Title 45 Part 46.

## Methods

### Model Formulation

We proposed an age-stratified Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated (SEPIARD-V) model to simulate SARS-CoV-2 transmission dynamics and

the effect of various vaccination scenarios (Appendix 1 Figure) (14). The SEPIARD-V model acknowledges that persons who are initially asymptomatic and later develop symptoms transmit the virus while in the presymptomatic phase. A 2020 study of presymptomatic transmission of SARS-CoV-2 in Singapore provided evidence of COVID-19 transmission 1–3 days before symptom onset (15). The model was suitable for studying the transmission dynamics of COVID-19 in Ghana because of the growing evidence that both symptomatic and asymptomatic patients transmit the infection, regardless of their symptomatic status (16,17). Our model, therefore, assumed that presymptomatic, asymptomatic, and symptomatic persons contributed to transmission. Our model also assumed that immunity from both natural infection and vaccination waned over time, making reinfection possible (Table 1; Appendix 1). An effective reproduction number ( $R_t$ ) of 3.13 was assumed for the virus in the main analysis to represent the virus strain that first hit Ghana in the spring of 2020, referred to as the initial strain in this study (Armachie et al., unpub. data, <https://doi.org/10.20944/preprints202104.0125.v1>). A higher  $R_t$  of 5.35 was assumed for the Delta variant in the scenario analyses, with a reduced vaccine efficacy of 67% for the AZD1222 vaccine (32; Pearson et al., unpub. data, <https://doi.org/10.1101/2021.12.19.21268038>). Our model was run for 500 days to allow enough time for the first wave of the epidemic to subside and to include observations relevant to when the second wave began to emerge.

### Age Groups and Contact Matrices

Because of the strong evidence of assortative mixing between age groups in sub-Saharan Africa (33,34), we incorporated a contact matrix between age groups into the model. We stratified the population was stratified into 3 groups: <25 years, 25–64 years, and ≥65 years of age. Two contact matrices were adapted from studies in Uganda (main matrix) and Ethiopia (second matrix) (33,35). The main matrix suggested that, on average, the within-group contact rate among persons <25 years of age was 23.58 per day; for persons 25–64 years of age, that contact rate was 15.05 per day; and for persons ≥65 years of age, the contact rate was 0.54 per day (33). For the second matrix, on average, the within-group daily contact rate was 8.2 among persons <25 years of age, 7.8 for persons 25–64 years of age, and 1.6 for persons ≥65 years of age (35). The population breakdown for Ghana was 56.08% <25 years of age ( $n = 17,272,640$ ), 39.48% 25–64 years of age ( $n = 12,159,840$ ), and 4.44% ≥65 years of age ( $n = 1,367,520$ ) (36) (Appendix 1).

## Scenario Analyses

Our analysis aimed to determine which age group should be prioritized in the case of limited vaccine supply under different rollout speeds. We analyzed multiple scenarios, looking at a percentage of each sub-population vaccinated when prioritizing different age groups, with coverage calculated for 1 million people using the 2021 population (37). The primary scenarios, by percentage of persons vaccinated in each age group, were as follows: (i) 73.1% of persons  $\geq 65$  years of age; (ii) 8.2% of persons 25–64 years of age; (iii) 5.8% of persons  $< 25$  years of age; and (iv) 3.4% of persons  $< 65$  years of age. We also assessed projected outcomes of vaccinating each age group at the same rate without prioritization (v). We used 2 rollout speeds (daily vaccination rates) in each scenario, assuming 2 million doses can be exhausted in 3 months and 6 months (Appendix 1 Tables 1–3). Finally, we performed analyses for 2 additional scenarios by changing the assumptions on vaccine supplies. First, the number of people to be vaccinated was either halved or doubled. Hence, we assumed enough vaccines were available for 500,000 persons (1 million doses) and 2,000,000 persons (4 million doses). We repeated our age-specific scenario analysis using the second contact matrix, adapted from Trentini et al. (35).

## Analysis

We solved our model's system of ordinary differential equations according to the Runge-Kutta 4 meth-

od in the deSolve package in R version 4.1.1 (The R Foundation for Statistical Computing, <https://www.r-project.org>). We estimated the number of infections and deaths averted in the general population and compared them across all study scenarios. We assessed the percent of the population who were symptomatic at the peak, those who were ever infected (cumulative infections), and those who died (cumulative deaths) (Appendix 1; Appendix 2).

## Results

### Symptomatic Infections at the Peak under the Main Scenario of Vaccinating 1 Million Persons

The following results of our main analysis assumed an  $R_t$  of 3.13 for the initial strain. We demonstrated that vaccinating 1 million persons  $< 25$  years of age in 3 months was associated with the lowest percentage (6.75%) of symptomatic persons in the population at the peak. However, prioritizing the elderly ( $\geq 65$  years of age) resulted in the highest percentage of symptomatic persons (7.19%) at the peak, given a 3-month rollout using the main matrix. If the rollout period was increased to 6 months, prioritizing persons  $< 25$  years of age also resulted in the lowest symptomatic percentages (7.01%) using the main matrix. The second matrix suggested that focusing vaccination initiatives on persons 25–64 years of age was associated with the lowest percentage of symptomatic infections (6.96%) (Tables 2, 3; Figure 1).

**Table 1.** Parameter values for age-stratified SEPIARD-V COVID-19 model to assess health outcomes of COVID-19 vaccination strategies, Ghana\*

Parameter	Symbol	Value	References
Mean latency period which is the period from exposure to infectiousness	1/k	1.85 d	Abbasi et al. (18), Liu et al. (19)
Mean duration of being infectious and symptomatic	1/f	15.7 d	Cai et al. (20), Xing et al. (21)
Mean duration of being infectious and asymptomatic	1/q	7.25 d	Ma et al. (22), Byrne et al. (23)
Mean duration of being infectious and presymptomatic	1/c	2.9 d	Tindale et al. (24), Byrne et al. (23)
Reproduction number for the initial strain	R	3.13	Armachie et al., unpub. data, <a href="https://doi.org/10.20944/preprints202104.0125.v1">https://doi.org/10.20944/preprints202104.0125.v1</a>
Reproduction number for the Delta strain	R	5.35	Pearson et al., unpub. data, <a href="https://doi.org/10.1101/2021.12.19.21268038">https://doi.org/10.1101/2021.12.19.21268038</a>
Probability of exposed person becoming presymptomatically infected	$\delta$	0.30	Chen et al. (25), Buitrago-Garcia et al. (26)
Vaccine efficacy against infection	$\sigma$	0.745	Knoll et al. (27)
Relative transmissibility of asymptomatic persons	u	0.75	CDC (28)
Relative transmissibility of presymptomatic persons	r	0.75	CDC (28)
Mean duration of immunity after vaccination	$\chi$	182 d	Iacobucci (29)
Mean duration of immunity after natural infection	w	365 d	Good and Hawkes (30)
Age-specific case-fatality ratio	z	0.002 for $< 25$ y, 0.005 for 25–64 y, 0.048 for $\geq 65$ y	Our World in Data (January 26, 2021–November 12, 2021; 22), Lawal (31)
Daily vaccination rate	v	Varied by 0.00009–0.0163977 $d^{-1}$ per person	Estimated

\*CDC, Centers for Disease Control and Prevention; SEPIARD-V, Susceptible-Exposed-Presymptomatic-Symptomatic-Recovered-Dead-Vaccinated.

**Table 2.** Scenario analysis of outcomes in the total population under various vaccination scenarios, using the main matrix method for the initial strain, Ghana

Vaccine prioritization by age group, y	Scenario, % infections					
	500,000 vaccinated in 3 mo	500,000 vaccinated in 6 mo	1 million vaccinated in 3 mo	1 million vaccinated in 6 mo	2 million vaccinated in 3 mo	2 million vaccinated in 6 mo
<b>Symptomatic infections at peak</b>						
Only ≥65	7.22	7.24	7.19	7.22	7.16	7.19
25–64	7.09	7.17	6.92	7.09	6.61	6.92
<25	7.01	7.13	6.75	7.01	6.26	6.75
<65	7.03	7.15	6.81	7.03	6.37	6.81
Same rate across age groups	7.04	7.15	6.83	7.04	6.40	6.83
<b>Cumulative infections</b>						
Only ≥65	172.88	173.50	172.09	172.88	171.33	172.09
25–64	170.80	172.57	167.44	170.80	161.00	167.44
<25	170.04	172.20	165.76	170.04	157.17	165.76
<65	170.28	172.43	166.19	170.28	158.20	166.19
Same rate across age groups	170.41	172.39	166.44	170.41	158.51	166.44
<b>Deaths</b>						
Only ≥65	0.18	0.19	0.17	0.18	0.17	0.17
25–64	0.19	0.19	0.19	0.19	0.18	0.19
<25	0.19	0.19	0.19	0.19	0.18	0.19
<65	0.19	0.19	0.19	0.19	0.18	0.19
Same rate across age groups	0.19	0.19	0.19	0.19	0.18	0.19

**Cumulative Infections under the Main Scenario of Vaccinating 1 Million Persons**

Our results suggest that vaccinating persons <25 years of age was associated with the largest number of cumulative infections averted in Ghana under the assumption of vaccinating 1 million people in 3 months (2,653,676 cases), whereas vaccinating persons ≥65 years of age was associated with the smallest number averted (702,432 cases) (Figure 2). We also found that vaccinating persons <25 years of age should be prioritized when the population was vaccinated at a slower rate (over 6 months) or when the vaccine supply doubled or halved (Table 2). The

results were sensitive to a change in the contact matrix (Table 3).

**Cumulative Deaths Averted under the Main Scenario of Vaccination of 1 Million Persons**

Vaccinating the elderly (≥65 years of age) could avert >7,000 deaths if 1 million people were vaccinated over 3 months, assuming the main contact matrix, and >4,000 deaths would be averted if the elderly population was vaccinated over 6 months. The number of deaths prevented was the lowest when persons <25 years of age were prioritized in both vaccination time frames (2,317 in 3 months vs. 1,157 in 6 months),

**Table 3.** Scenario analysis of outcomes in the total population under various vaccination scenarios using the second matrix method for the initial strain, Ghana

Vaccine prioritization by age group, y	Scenario, % infections					
	500,000 vaccinated in 3 mo	500,000 vaccinated in 6 mo	1 million vaccinated in 3 mo	1 million vaccinated in 6 mo	2 million vaccinated in 3 mo	2 million vaccinated in 6 mo
<b>Symptomatic infections at peak</b>						
Only ≥65	7.02	7.10	6.92	7.02	6.82	6.92
25–64	6.96	7.07	6.75	6.96	6.35	6.75
<25	6.99	7.09	6.79	6.99	6.42	6.79
<65	6.97	7.08	6.76	6.97	6.35	6.76
Same rate across age groups	6.98	7.08	6.76	6.98	6.35	6.76
<b>Cumulative infections</b>						
Only ≥65	177.71	179.61	175.36	177.71	173.19	175.36
25–64	178.22	180.28	174.26	178.22	166.42	174.26
<25	178.62	180.48	174.95	178.62	167.74	174.95
<65	178.39	180.48	174.42	178.39	166.69	174.42
Same rate across age groups	178.30	180.33	174.25	178.30	166.13	174.25
<b>Deaths</b>						
Only ≥65	0.19	0.20	0.18	0.19	0.17	0.18
25–64	0.21	0.22	0.21	0.21	0.19	0.21
<25	0.22	0.22	0.22	0.22	0.21	0.21
<65	0.22	0.22	0.21	0.22	0.20	0.21
Same rate across age groups	0.21	0.22	0.21	0.21	0.20	0.21

assuming the main contact matrix (Figure 2). Vaccinating the elderly ( $\geq 65$  years of age) remained the best option to reduce deaths, regardless of the mixing patterns (Tables 2, 3; Figures 1, 2).


### Varying Vaccine Supply to Vaccinate 500,000 or 2 Million Persons

Similar to the base case scenarios of vaccinating 1 million persons, prioritizing persons  $< 25$  years of age was associated with the lowest percentage of cumulative infections if 500,000 or 2 million persons were vaccinated in 3 or 6 months (Table 2). However, simulations using the second matrix reported mixed results. For example, prioritizing the elderly seemed to be the best strategy for lowering cumulative infections when vaccine supplies were only enough for


500,000 people (177.71% for 3 months and 179.61% for 6 months). In contrast, vaccinating each age group at the same rate was preferred when the supply was enough to vaccinate 2 million persons (166.13% for 3 months and 174.25% for 6 months) (Table 3). Prioritizing the elderly ( $\geq 65$  years of age) remained the strategy of choice to specifically lower COVID-19 mortality for both matrices (Tables 2, 3).

### Comparing Outcomes for the Initial and Delta Variants in the Absence of Vaccination

In the absence of vaccination, the scenario analysis for the Delta variant using the main matrix suggested 10.29% of symptomatic persons at the peak, 231.24% of persons having cumulative incidence of COVID-19, and 0.28% deaths in the population (Appendix 1 Table



**Figure 1.** Effects of various vaccination scenarios on symptomatic infections at peak (upper panels), cumulative infections (middle panels), and deaths (lower panels) as a percentage of the general population, Ghana. The assessment used 2 different contact matrices in the main analysis and an effective reproductive number of 3.13 for the initial strain. A) Results assuming 1 million persons were vaccinated in 3 months. B) Results assuming 1 million persons were vaccinated in 6 months. Percentage of cumulative infections is  $> 100\%$  because of waning immunity from natural infection and vaccination.



**Figure 2.** Effects of various vaccination scenarios on the number of cumulative infections averted (upper panels) and the number of deaths averted (lower panels) in the general population, Ghana. The assessment used 2 different contact matrices in the main analysis and an effective reproductive number of 3.13 for the initial strain. A) Results assuming 1 million persons were vaccinated in 3 months. B) Results assuming 1 million persons were vaccinated in 6 months.

4). Those percentages were higher than those for the initial strain, which were calculated as 7.26% of symptomatic persons at peak, 174.37% of persons having cumulative incidence of COVID-19, and 0.20% deaths in the population (Figure 1). Those findings were consistent with the results from the second matrix (Appendix 1 Table 5). In the Delta variant scenario, the percentage of symptomatic persons at the peak was slightly lower with the second matrix (10.14%) than with the main matrix (10.29%). However, cumulative infections (238.73%) and deaths (0.31%) were higher with the second matrix in the Delta variant scenario (Appendix 1 Tables 4, 5).

**Impact of Vaccination Strategies on Symptomatic Infections at the Peak Due to the Delta Variant**

In analyzing vaccine prioritization for the Delta variant scenario, we found that prioritizing per-

sons <25 years of age was associated with the lowest percentage of symptomatic infections at the peak, regardless of the available vaccine doses and rollout speed, using the main matrix (Table 4). As for the initial strain scenario, prioritizing persons <65 years of age was associated with the lowest percentage of symptomatic infections at the peak (9.89%) under the assumption of vaccinating 1 million persons over 3 months using the second matrix for the Delta variant (Table 5).

**Impact of Vaccination Strategies on Cumulative Infections and Deaths Caused by Delta Variant**

The scenario where 1 million people were vaccinated over 3 months suggested that focusing on persons <25 years of age had the lowest value of cumulative infections (226.32%) for the Delta variant,

**Table 4.** Comparing outcomes for the Delta variant if 1 million persons were vaccinated under the various vaccination strategies using the main matrix method, Ghana

Vaccine prioritization by age group, y	Scenario, % infections			
	Initial strain, 3 mo	Delta variant, 3 mo	Initial strain, 6 mo	Delta variant, 6 mo
<b>Symptomatic infections at peak</b>				
Only ≥65	7.19	10.22	7.22	10.25
25–64	6.92	10.08	7.09	10.18
<25	6.75	9.99	7.01	10.14
<65	6.81	10.02	7.03	10.15
Same rate across age groups	6.83	10.03	7.04	10.16
<b>Cumulative infections</b>				
Only ≥65	172.09	228.43	172.88	229.50
25–64	167.44	227.00	170.80	229.07
<25	165.76	226.32	170.04	228.77
<65	166.19	226.50	170.28	228.87
Same rate across age groups	166.44	226.55	170.41	228.89
<b>Deaths</b>				
Only ≥65	0.17	0.25	0.18	0.26
25–64	0.19	0.27	0.19	0.28
<25	0.19	0.28	0.19	0.28
<65	0.19	0.27	0.19	0.28
Same rate across age groups	0.19	0.27	0.19	0.28

findings that paralleled our analysis of the initial strain (165.76%). Prioritizing persons <25 years of age was the best option to minimize cumulative infections in the population with a 6-month rollout for the Delta variant (228.77%) (Table 4). Importantly, the results on cumulative infections of the second matrix suggested the elderly (235.15%) should be prioritized for vaccination first for the Delta variant with a 6-month rollout (Table 5). Prioritizing the elderly remained the best strategy for lowering deaths in the population for the initial strain and the Delta variant in all the scenarios (Tables 4, 5; Appendix 1 Tables 4, 5).

## Discussion

Vaccination is the best tool to control the spread of SARS-CoV-2 and minimize the burden of COVID-19 globally. Because Ghana primarily relies on multilateral donations for their COVID-19 vaccine supply, there is a need to determine the best vaccine optimization strategies to minimize deaths, cumulative case counts, and epidemic peaks over a relatively short period. Using 2 contact matrices, we used an age-stratified mathematical model to answer the question of who should get vaccinated first when the vaccine supply is limited and when supplies are exhausted over 3 and 6 months. Our findings suggest that, for both the initial strain and the Delta variant, prioritizing persons <25 years of age for vaccination would avert the most cumulative infections and prioritizing the elderly (≥65 years of age) would result in the lowest death counts.

Optimization of vaccine prioritization strategy is sensitive to the population structure. Prioritizing younger persons to avert cumulative infections is a finding that has been reported in other studies

(13,38,39). Bubar et al. concluded in their multicountry research that the cumulative incidence of COVID-19 was lowest when adults 20–49 years of age were prioritized, especially with a highly effective transmission-blocking vaccine (13). In Senegal, Diarra et al. used an age-structured dynamic mathematical model to explore various vaccination strategies and reported that prioritizing persons <60 years of age was associated with the lowest case burden (40). Those authors argued that countries with younger populations, such as Ghana, should prioritize vaccinating younger persons to minimize hospital costs and productivity loss.

As was the case for our team, most research teams conducting previous studies concluded that prioritizing the elderly was associated with the lowest mortality. However, Bubar et al. reported that persons 20–49 years of age should be prioritized to minimize mortality when transmission is low, when vaccine efficacy is lower in older adults, and when the vaccine is highly effective in blocking transmission. Buckner et al. reported results similar to those in our study and found that, to control deaths directly, the elderly should be vaccinated first, after stratifying young adults by essential worker status (41). Although the conclusions in that study and our study were similar, Buckner et al. used a dynamic approach in modeling vaccine allocation strategies that accounted for changes in the epidemiologic status of the population (shares of the population in different disease states) over 6 months using stochastic nonlinear programming techniques. In a vaccine optimization modeling study in India, Foy et al. concluded that prioritizing older adults (≥60 years of age) was associated with the most significant reduction in deaths, regardless of vaccine efficacy, control

measures, and rollout speed (38). Another modeling study by Chapman et al., using COVID-19 data from California, reported similar results (42); however, that study focused on identifying the groups to prioritize after healthcare workers and long-term facility residents received initial vaccine doses.

The differences in outcomes between the contact matrices in our study might be due to the much lower reported contact rates among the younger population in the matrix adapted from Trentini et al. (i.e., second matrix) (35). The study by Bubar et al. on vaccine optimization strategies across multiple countries, including South Africa, concluded the best vaccination strategy depended on the extent of mixing patterns (13). The use of 2 contact matrices reflects the degree to which decision makers should consider social interactions in the population before optimizing vaccination strategies when vaccine supplies are limited. Our findings demonstrate that the mixing pattern is relevant when the goal of the vaccination program is to minimize infection burden and the vaccine rollout takes place over an extended period. Thus, a population with lower contact rates among the older population would need to prioritize younger persons. However, contact patterns in the population may not be relevant if the goal of the vaccination program is to minimize deaths and vaccine uptake is high. Future studies might consider exploring differences observed using matrices of different settings; for example, rural versus urban and household versus community mixing.

As reported by Ko et al., the question of who should receive vaccinations first depends also on the objective for vaccination (minimizing cumulative infections or deaths) and the effective reproduction number (39). Thus, policymakers might need

to consider compromises in deciding the best vaccine allocation strategies. For example, prioritizing the elderly may lead to fewer deaths but higher case numbers, which could exacerbate economic loss due to a high case count in a younger population. The transmissibility of the circulating variant also might inform a vaccine optimization strategy. We did not see evidence of this effect in our study because the priority group remained the same for the Delta variant, which carried a higher reproduction number. Another study concluded vaccine optimization depended on the vaccine supply (42).

Although our study demonstrates the need to prioritize certain age groups to minimize the burden of COVID-19 in Ghana, depending on the objective of the program, other factors need to be considered to ensure people receive vaccinations when they become eligible. Employing targeted vaccine campaigns to minimize hesitancy among the prioritized group might be a necessary part of the program. Acheampong et al. reported the level of reluctance among older adults was lower than that for younger adults in Ghana (43). Likewise, a survey among persons >65 years of age in the United States found that 91% of the elderly were willing to get vaccinated (44). This reported vaccine hesitancy across different age groups suggests a need for campaigns to create an enabling environment and engage younger populations about their role in mitigating the pandemic.

The first limitation of our study is that our model was age-stratified only. Other demographic variables (e.g., occupation and comorbidity) might change a person’s COVID-19 infection risk and clinical prognosis (45). Second, our model did not include a hospitalization compartment. Thus, we

**Table 5.** Comparing outcomes for the Delta variant if 1 million persons were vaccinated under the various vaccination strategies using the second matrix methods, Ghana

Vaccine prioritization by age group, y	Scenario, % infections			
	Initial strain, 3 mo	Delta variant, 3 mo	Initial strain, 6 mo	Delta variant, 6 mo
<b>Symptomatic infections at peak</b>				
Only ≥65	6.92	9.96	7.02	10.04
25–64	6.75	9.90	6.96	10.01
<25	6.79	9.90	6.99	10.01
<65	6.76	9.89	6.97	10.01
Same rate across age groups	6.76	9.89	6.98	10.01
<b>Cumulative infections</b>				
Only ≥65	175.36	232.82	177.71	235.15
25–64	174.26	234.30	178.22	236.48
<25	174.95	234.44	178.62	236.57
<65	174.42	232.29	178.39	236.50
Same rate across age groups	174.25	234.13	178.30	236.43
<b>Deaths</b>				
Only ≥65	0.18	0.26	0.19	0.28
25–64	0.21	0.31	0.21	0.31
<25	0.22	0.31	0.22	0.31
<65	0.21	0.31	0.22	0.31
Same rate across age groups	0.21	0.31	0.21	0.31



could not evaluate the effects of the Omicron variant, for which vaccines demonstrated effectiveness against severe infections but modest effectiveness against infection. Third, the contact matrices we used were adapted from other countries in Africa. Those countries had similar demographic distributions as Ghana, and we assumed that the frequency of contact in the population would be similar. Fourth, we did not have data to represent the rural and urban differences in contact matrices in Ghana. Fifth, our model design specified the symptomatic period to be the same for persons who recovered from COVID-19 and those who died from it. Sixth, the highly transmissible Omicron variant was not included in our study because of limited evidence of the effectiveness of vaccines against infection from that variant (46). Last, our model accounted for vaccine effectiveness against infection but did not account for the reduction of the case-fatality ratio if a person was vaccinated and still became infected.

In conclusion, we used an age-stratified compartmental model to assess the impact of various COVID-19 vaccine allocation strategies in Ghana. Our study reiterates the need to increase vaccination rates by ensuring increased vaccine supplies and faster rollout speed. Vaccinating persons <25 years of age was associated with the highest numbers of cumulative infections averted for the initial strain and the Delta variant. Prioritizing persons ≥65 years of age was associated with the lowest deaths in the population. Our findings indicate that vaccine prioritization strategies in Ghana, or in any country, depend on the country's policy objectives, population structure, mixing patterns, and vaccine supply.

S.K.O. and I.C.H.F. conceptualized the study; S.K.O. programmed the model in R and ran the simulations and drafted the manuscript under I.C.H.F.'s supervision. J.S.S., K.L.S., G.C., and B.J.C. provided consultation to S.K.O. and I.C.H.F. All authors edited, reviewed, and approved the manuscript.

S.K.O. is a paid intern at Ionis Pharmaceuticals; the financial relationship does not affect the content of the article. B.J.C. was a consultant for Roche and Sanofi Pasteur. All other co-authors declare no competing interest.

### About the Author

Dr. Ofori is a postdoctoral curriculum and research fellow in the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health. Her research interests are infectious disease epidemiology and mathematical modeling.

### References

1. Ghana Health Service. COVID-19 Ghana's outbreak response management updates. 2022 [cited 2023 Jan 06]. <https://ghanahealthservice.org/covid19/archive.php>
2. Ofori SK, Schwind JS, Sullivan KL, Cowling BJ, Chowell G, Fung IC-H. Transmission dynamics of COVID-19 in Ghana and the impact of public health interventions. *Am J Trop Med Hyg.* 2022;107:175-9. <https://doi.org/10.4269/ajtmh.21-0718>
3. Quakyi NK, Agyemang Asante NA, Nartey YA, Bediako Y, Sam-Agudu NA. Ghana's COVID-19 response: the Black Star can do even better. *BMJ Glob Health.* 2021;6:e005569. <https://doi.org/10.1136/bmjgh-2021-005569>
4. Alhassan RK, Aberese-Ako M, Doegah PT, Immurana M, Dalaba MA, Manyeh AK, et al. COVID-19 vaccine hesitancy among the adult population in Ghana: evidence from a pre-vaccination rollout survey. *Trop Med Health.* 2021;49:96. <https://doi.org/10.1186/s41182-021-00357-5>
5. World Health Organization Africa. More COVID-19 vaccines arrive in Ghana. 2021. [cited 2022 Dec 6]. <https://www.afro.who.int/news/more-covid-19-vaccines-arrive-ghana>
6. Ghana Health Service. COVID-19 Ghana's outbreak response management updates. 2020 [cited 2022 Feb 21]. <https://ghanahealthservice.org/covid19/archive.php>
7. Botwe BO, Antwi WK, Adusei JA, Mayeden RN, Akudjedu TN, Sule SD. COVID-19 vaccine hesitancy concerns: Findings from a Ghana clinical radiography workforce survey. *Radiography (Lond).* 2022;28:537-44. <https://doi.org/10.1016/j.radi.2021.09.015>
8. Quashie PK, Mutungi JK, Dzabeng F, Oduro-Mensah D, Oporum PC, Tapela K, et al. Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana. *Wellcome Open Res.* 2021;6:173. <https://doi.org/10.12688/wellcomeopenres.16890.1>
9. Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, et al. The impact of vaccination to control COVID-19 burden in the United States: a simulation modeling approach. *PLoS One.* 2021;16:e0254456. <https://doi.org/10.1371/journal.pone.0254456>
10. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. *Clin Infect Dis.* 2021;73:2257-64. <https://doi.org/10.1093/cid/ciab079>
11. Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? *Sci Adv.* 2021;7:eabf1374. <https://doi.org/10.1126/sciadv.abf1374>
12. Mumtaz GR, El-Jardali F, Jabbour M, Harb A, Abu-Raddad LJ, Makhoul M. Modeling the impact of COVID-19 vaccination in Lebanon: a call to speed-up vaccine roll out. *Vaccines (Basel).* 2021;9:697. <https://doi.org/10.3390/vaccines9070697>
13. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science.* 2021;371:916-21. <https://doi.org/10.1126/science.abe6959>
14. University of British Columbia Department of Zoology. COVID-19 models lecture. 2020 [cited 2020 Nov 15]. [https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID\\_Models.pdf](https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID_Models.pdf)
15. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:411-5. <https://doi.org/10.15585/mmwr.mm6914e1>
16. Li Y, Shi J, Xia J, Duan J, Chen L, Yu X, et al. Asymptomatic

- and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: a retrospective single center study. *Front Microbiol.* 2020;11:1570. <https://doi.org/10.3389/fmicb.2020.01570>
17. Zhao H, Lu X, Deng Y, Tang Y, Lu J. COVID-19: asymptomatic carrier transmission is an underestimated problem. *Epidemiol Infect.* 2020;148:e116-e. <https://doi.org/10.1017/S0950268820001235>
  18. Abbasi Z, Zamani I, Mehra AHA, Shafieirad M, Ibeas A. Optimal control design of impulsive SQEIR epidemic models with application to COVID-19. *Chaos Solitons Fractals.* 2020;139:110054. <https://doi.org/10.1016/j.chaos.2020.110054>
  19. Liu Z, Magal P, Seydi O, Webb GA. COVID-19 epidemic model with latency period. *Infect Dis Model.* 2020;5:323–37. <https://doi.org/10.1016/j.idm.2020.03.003>
  20. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy.* 2020;75:1742–52. <https://doi.org/10.1111/all.14309>
  21. Xing YH, Ni W, Wu Q, Li WJ, Li GJ, Wang WD, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. *J Microbiol Immunol Infect.* 2020;53:473–80. <https://doi.org/10.1016/j.jmii.2020.03.021>
  22. Ma S, Zhang J, Zeng M, Yun Q, Guo W, Zheng Y, et al. Epidemiological parameters of COVID-19: cases series study. *J Med Internet Res.* 2020;22:e19994. <https://doi.org/10.2196/19994>
  23. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. *BMJ Open.* 2020;10:e039856. <https://doi.org/10.1136/bmjopen-2020-039856>
  24. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for transmission of COVID-19 prior to symptom onset. *eLife.* 2020;9:e57149. <https://doi.org/10.7554/eLife.57149>
  25. Chen M, Li M, Hao Y, Liu Z, Hu L, Wang L. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. *Inf Fusion.* 2020;64:252–8. <https://doi.org/10.1016/j.inffus.2020.08.002>
  26. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. *PLoS Med.* 2020;17:e1003346-e.
  27. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet.* 2021;397:72–4. [https://doi.org/10.1016/S0140-6736\(20\)32623-4](https://doi.org/10.1016/S0140-6736(20)32623-4)
  28. Centers for Disease Control and Prevention. Pandemic planning scenarios. 2020 [cited 2020 Nov 12]. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>
  29. Iacobucci G. Covid-19: Protection from two doses of vaccine wanes within six months, data suggest. *BMJ.* 2021;374:n2113. <https://doi.org/10.1136/bmj.n2113>
  30. Good MF, Hawkes MT. The interaction of natural and vaccine-induced immunity with social distancing predicts the evolution of the COVID-19 Pandemic. *MBio.* 2020; 11:e02617–20. <https://doi.org/10.1128/mBio.02617-20>
  31. Lawal Y. Africa's low COVID-19 mortality rate: A paradox? *Int J Infect Dis.* 2021;102:118–22. <https://doi.org/10.1016/j.ijid.2020.10.038>
  32. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. *N Engl J Med.* 2021;385:585–94. <https://doi.org/10.1056/NEJMoa2108891>
  33. le Polain de Waroux O, Cohuet S, Ndazima D, Kucharski AJ, Juan-Giner A, Flasche S, et al. Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. *BMC Infect Dis.* 2018;18:172. <https://doi.org/10.1186/s12879-018-3073-1>
  34. Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. *PLoS One.* 2014;9:e104786. <https://doi.org/10.1371/journal.pone.0104786>
  35. Trentini F, Guzzetta G, Galli M, Zardini A, Manenti F, Putoto G, et al. Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia. *BMC Med.* 2021;19:89. <https://doi.org/10.1186/s12916-021-01967-w>
  36. Central Intelligence Agency. The world factbook. 2020 [cited 2022 Jan 15]. <https://www.cia.gov/the-world-factbook>
  37. Anaadom P. Ghana: population hits 30.8 million – Greater Accra most populous region – GSS. *Ghana Today.* 2021 Sep 22 [cited 2022 Dec 6]. <https://ghanatoday.gov.gh/news/ghanas-population-hits-30-8-million-greater-accra-most-populous-region-gss/>
  38. Foy BH, Wahl B, Mehta K, Shet A, Menon GI, Britto C. Comparing COVID-19 vaccine allocation strategies in India: a mathematical modelling study. *Int J Infect Dis.* 2021;103:431–8. <https://doi.org/10.1016/j.ijid.2020.12.075>
  39. Ko Y, Lee J, Kim Y, Kwon D, Jung E. COVID-19 vaccine priority strategy using a heterogenous transmission model based on maximum likelihood estimation in the Republic of Korea. *Int J Environ Res Public Health.* 2021;18:6469. <https://doi.org/10.3390/ijerph18126469>
  40. Diarra M, Kebir A, Talla C, Barry A, Faye J, Louati D, et al.; REPAIR consortium. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study. *BMJ Glob Health.* 2022;7:e007236. <https://doi.org/10.1136/bmjgh-2021-007236>
  41. Buckner JH, Chowell G, Springborn MR. Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers. *Proc Natl Acad Sci U S A.* 2021;118:e2025786118. <https://doi.org/10.1073/pnas.2025786118>
  42. Chapman LAC, Shukla P, Rodríguez-Barraquer J, Shete PB, León TM, Bibbins-Domingo K, et al. Risk factor targeting for vaccine prioritization during the COVID-19 pandemic. *Sci Rep.* 2022;12:3055. <https://doi.org/10.1038/s41598-022-06971-5>
  43. Acheampong T, Akorsikumah EA, Osaekwapong J, Khalid M, Appiah A, Amuasi JH. Examining vaccine hesitancy in sub-saharan Africa: a survey of the knowledge and attitudes among adults to receive COVID-19 vaccines in Ghana. *Vaccines (Basel).* 2021;9:814. <https://doi.org/10.3390/vaccines9080814>
  44. Nikolovski J, Koldijk M, Weverling GJ, Spertus J, Turakhia M, Saxon L, et al. Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. *PLoS one.* 2021;16:e0251963-e. <https://doi.org/10.1371/journal.pone.0251963>
  45. Dembek ZF, Schwartz-Watjen KT, Swiatecka AL, Broadway KM, Hadeed SJ, Mothershead JL, et al. Coronavirus disease 2019 on the heels of Ebola virus disease


- in West Africa. *Pathogens*. 2021;10:1266. <https://doi.org/10.3390/pathogens10101266>
46. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. *N Engl J Med*. 2022;386:1532–46. <https://doi.org/10.1056/NEJMoa2119451>

Address for correspondence: Isaac Chun-Hai Fung, PO Box 7989, Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA 30458-7989, USA; email: [cfung@georgiasouthern.edu](mailto:cfung@georgiasouthern.edu)

June 2022

# Parasitic Infections

- Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA
- Detection of SARS-CoV-2 B.1.351 (Beta) Variant through Wastewater Surveillance before Case Detection in a Community, Oregon, USA
- Foodborne Illness Outbreaks Reported to National Surveillance, United States, 2009–2018
- Antimicrobial-Resistant *Shigella* spp. in San Diego, California, USA, 2017–2020
- Characterization of Healthcare-Associated and Community-Associated *Clostridioides difficile* Infections among Adults, Canada, 2015–2019
- Divergent Rabies Virus Variant of Probable Bat Origin in 2 Gray Foxes, New Mexico, USA
- Effects of Acute Dengue Infection on Sperm and Virus Clearance in Body Fluids of Men
- Risk Factors for SARS-CoV-2 Infection and Illness in Cats and Dogs
- *Angiostrongylus cantonensis* Nematode Invasion Pathway, Mallorca, Spain [
- Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016
- Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo [
- Retrospective Genomic Characterization of a 2017 Dengue Virus Outbreak, Burkina Faso
- Geographic Origin and Vertical Transmission of *Leishmania infantum* Parasites in Hunting Hounds, United States
- Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain



- Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021
- Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon
- Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
- Outbreak of Imported Seventh Pandemic *Vibrio cholerae* O1 El Tor, Algeria, 2018
- *Burkholderia pseudomallei* in Environment of Adolescent Siblings with Melioidosis, Kerala, India, 2019
- Zoonotic Transmission of Diphtheria from Domestic Animal Reservoir, Spain
- Detecting SARS-CoV-2 Omicron B.1.1.529 Variant in Wastewater Samples by Using Nanopore Sequencing
- Lyme Disease, Anaplasmosis, and Babesiosis, Atlantic Canada
- Public Health Response to Multistate *Salmonella* Typhimurium Outbreak Associated with Prepackaged Chicken Salad, United States, 2018
- New Variant of *Vibrio parahaemolyticus*, Sequence Type 3, Serotype O10:K4, China, 2020
- *Fasciolopsis buski* Detected in Humans in Bihar and Pigs in Assam, India
- Identification of Human Case of Avian Influenza A(H5N1) Infection, India
- Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
- Recombinant BA.1/BA.2 SARS-CoV-2 Virus in Arriving Travelers, Hong Kong, February 2022
- SARS-CoV-2 Breakthrough Infections among US Embassy Staff Members, Uganda, May–June 2021
- Multistate Outbreak of Infection with SARS-CoV-2 Omicron Variant after Event in Chicago, Illinois, USA, 2021
- Molecular Diagnosis of *Pseudoterranova decipiens* Sensus Stricto Infections, South Korea, 2002–2020
- Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease
- Horse-Specific Cryptosporidium Genotype in Human with Crohn's Disease and Arthritis

**EMERGING  
INFECTIOUS DISEASES**

To revisit the June 2022 issue, go to:  
<https://wwwnc.cdc.gov/eid/articles/issue/28/6/table-of-contents>

# Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana

## Appendix 1

### Methods

#### Model equations

The total population of Ghana,  $N$ , is assumed to be a constant and equals the sum of the compartments representing individuals with different disease statuses (including COVID-19-specific deaths) at any time during the simulation and that births and deaths from natural (non-COVID-19) causes do not affect the infection dynamics in the population:

$$N = S + E + P + I + A + R + V + D \text{ (Eq. 1)}$$

Following the assumption of a frequency-dependent model, we define the force of infection,  $\lambda$ , as a combination of infection terms with symptomatic, asymptomatic, and pre-symptomatic individuals, each contributing to the transmission process as follows:

$$\lambda = \frac{\beta(I+uA+rP)}{N} \text{ (Eq. 2),}$$

where the contributions of asymptomatic and presymptomatic individuals are fractions  $u$  and  $r$  of that of the symptomatic individuals.

The set of ordinary differential equations (ODE) that defines the progression of susceptible individuals through different disease statuses upon infection and a vaccinated and immune status upon vaccination and their re-entry into the susceptible state due to waning immunity is described below:

$$dS/dt = (-\lambda S) + wR - (v\sigma S) + \chi V \text{ (Eq. 3)}$$

$$dE/dt = \lambda S - kE \text{ (Eq. 4)}$$

$$dP/dt = \delta kE - cP \text{ (Eq. 5)}$$

$$dI/dt = cP - (1 - z)fI - zfI \text{ (Eq. 6)}$$

$$dA/dt = (1 - \delta)kE - qA \text{ (Eq. 7)}$$

$$dR/dt = (1 - z)fI + qA - wR \text{ (Eq. 8)}$$

$$dD/dt = zfI \text{ (Eq. 9)}$$

$$dV/dt = v\sigma S - \chi V \text{ (Eq. 10)}$$

$$dC/dt = kE \text{ (Eq. 11)}$$

In the SEPIARD-V model, the population is initially susceptible until an infectious individual is introduced. After contact with an infectious person, susceptible individuals are infected at a rate of  $\lambda$  (force of infection). While in the latent period (E), they do not transmit the virus. Individuals leave the latent period at a rate of  $k$  and can either become asymptotically (A) or pre-symptomatically infectious (P). Asymptomatic individuals will recover (move to the R compartment) at a rate of  $q$  without showing any symptoms (1,2). Pre-symptomatic infectious individuals become symptomatic (I) at a rate of  $c$ . The mean duration of the symptomatic period is defined as  $1/f$ . A fraction  $z$  of symptomatic individuals will die from COVID-19 (move to the D compartment) while the other fraction  $(1-z)$  will recover (move to the R compartment). Susceptible individuals become fully vaccinated (move to the V compartment) at a rate of  $v$  per day, while the vaccine is assumed to have an efficacy (or effectiveness) of  $\sigma$ .

### Model parameters

In our model, after susceptible individuals are exposed, the latent period, which is the period from exposure to infectiousness, is  $1/k$  and is assumed to have a mean of 1.85 days (3,4). Once exposed, a third ( $\delta$ ) of individuals become pre-symptomatically infected, and the rest  $(1-\delta)$  become asymptomatic (5,6). The mean pre-symptomatic period,  $1/c$ , is assumed to be 2.9 days (7). The mean duration of infectiousness for symptomatic individuals ( $1/f$ ) is 15.7 days, and that of asymptomatic individuals ( $1/q$ ) is 7.25 days (8-11). The transmission rate,  $\beta$ , is estimated from the reproduction number (R) using the formula  $(1 - \delta) \left( \frac{u\beta}{q} \right) + \delta \left( \frac{r\beta}{c} + \frac{\beta}{f} \right)$  (12), assuming a value of 3.13 for the initial strain as assessed by Armachie and colleagues (unpub. data, <https://doi.org/10.20944/preprints202104.0125.v1>). This value would be updated in our scenario analysis of the delta variant. As we assumed some individuals were recovered and temporarily immune at the beginning of the simulation (see 'Model initialization' below), the transmission

rate was derived from an effective reproductive number of 3.13 for the initial strain and 5.35 for the Delta variant respectively. According to the CDC COVID-19 pandemic planning scenarios, the relative transmissibility of asymptomatic and pre-symptomatic individuals,  $u$  and  $r$ , are assumed to be 0.75, respectively (13). Two doses of the AstraZeneca COVID-19 vaccine were reported to have an efficacy ( $\sigma$ ) of 0.745 (14). This value would also be updated in our scenario analysis of the delta variant. Immunity is acquired from either natural infection or vaccination. Vaccination-induced immunity offers protection from infection for six months (180 days) and wanes at a rate of  $\chi$ , while that from natural infection,  $w$ , is about one year (365 days) (15). The rate of vaccination,  $v$ , is varied depending on the scenario. Once immunity wanes, individuals move back to the susceptible compartment. Details of model parameters are found in Appendix 1 Table 1.

### **Age-stratification**

The aforementioned SEPIARD-V model was further developed into an age-stratified model.

The idea of the age-stratified model was adapted from a modeling study by Keeling and White on vaccination strategies with an optimal number of cases and severity effects during Britain's 2009 H1N1 influenza pandemic (16). Our analysis would answer research questions similar to the Keeling and White study and include modifications to address issues pertinent to the COVID-19 pandemic in Ghana. With vaccine supplies available, policymakers would be interested in which epidemiological goal the vaccine would most impact.

A recent retrospective cohort study in Ghana by Ashninyo et al. reported that COVID-19 disproportionately affected the younger population with a mean age of 37.9 years, with the majority (56.64%) between 31 and 64 years (17). According to Ghana's demographics, 56.08% of the population is below 25 years, and 4.44% are 65 years or above (18). Therefore, the population was stratified into three groups: <25 years, 25-64 years, and 65+ years.

### **Age-stratified model formulation**

An age-stratified compartmental model assumes that population mixing is not homogeneous and the numbers of contact between members of age groups follow a specified contact matrix. The number of secondary cases caused by an infectious individual in a totally susceptible population is commonly known as the basic reproduction number. In the context of a heterogeneous-mixing model, the basic reproduction number is also known as a basic reproductive ratio and is the

largest eigenvalue of the next generation matrix (NGM) (19). Following the work of Towers and Feng (20), the reproduction number of an age-stratified model is equal to the product of the transmission coefficient  $\beta$ , the mean duration of infectiousness, and the largest eigenvalue of a matrix  $M$  that is defined by its elements  $M_{ij} = C_{ij} \left( \frac{N_i}{N_j} \right)$ , where  $C_{ij}$  is the contact matrix, and  $N_i$  and  $N_j$  are the numbers of individuals in age groups  $i$  and  $j$  respectively (21).

### Contact matrices used

Due to the strong evidence of assortative mixing between age groups in the general population of Uganda (22) and Kenya (23), the contact matrix of the population was considered in the modeling of vaccination allocation strategies in Ghana. As reported by Waroux and colleagues, the contact patterns of Uganda were adopted in this study because their matrix corresponds to the population groups used in this study (below 25 years, 25-64 years, and 65 years or above). There is also a similarity in the proportion of age structure between Uganda and Ghana. Waroux and colleagues used the survey method to study the contact patterns of residents in rural Uganda in 2014 and found that, on average, the within-group contact rate among individuals below 25 years is 23.58 per day; for those between 25-64 years, it was 15.05 per day and 0.54 per day for those above 64 years (22).

Therefore, the 3 by 3 contact matrix is:

	Below 25 y	25–64 y	65 y and above
Below 25 y	23.58	9.31	0.87
25–64 y	13.01	15.05	1.53
65 y and above	2.29	2.44	0.54

This contact matrix was corrected for reciprocity using methods described by Melegaro et al. in their study in Zimbabwe (24).

The second matrix was adapted from a study in Ethiopia by Trentini et al., who also used survey-type interviews to estimate age-specific patterns (25). The contact matrix was used due to the similar population structure to Ghana. Furthermore, the data on contact patterns were collected in 2019, prior to the COVID-19 pandemic, and may reflect recent contact rates. On average, the within-group contact rate among individuals below 25 years is 8.2 per day; for those between 25-64 years, it was 7.8 per day, and 1.6 per day for those above 64 years (22). The 3 by 3 contact matrix is:

	Below 25 y	25–64 y	65 y and above
Below 25 y	8.2	5	1
25–64 y	2	7.8	2.8
65 y and above	0.1	2.2	1.6

This contact matrix was then corrected for reciprocity using methods described by Melegaro in their study in Zimbabwe (26).

### Case-fatality ratio in the age-stratified model

The age-specific fatality ratios were calculated using data from Odikro and colleagues' study on the epidemiology of COVID-19 outbreak in Ghana (27). Using the total number of cases reported in their study (n=17,763) and the percentage of cases reported in each 10-year age group as of June 30, 2020, we calculated the percentage of cases in each age group as 23.85% for persons below 25 years, 70.65% for those between 25-64 years and 5.5% for 65+ years. For the cases reported among persons 20-29 years, we assumed that half of them occurred in persons between 20-24 years, and the other half occurred in those between 25-29 years. Next we calculated the expected number of cases for <25 years (n=4,236), 25-64 years (n=12,550) and elderly (n=977). The expected number of deaths was estimated for each age group assuming that 9% of the total deaths (n=117) deaths occurred among <25 years, 51% for 25-64 years and, 40% among the elderly (65+) (27,28). Finally, we calculated the age-specific case fatality ratios as the ratio between the number of deaths in each age group by the number of cases in each age group. Hence, the estimates were 0.002 for <25 years, 0.005 for 25-64 years and 0.048 for 65+ years. All other variables except the vaccination rate remained the same as described in Appendix 1 Table 1.

### Model initialization

The model's system of ODE was solved following the Runge-Kutta 4 method in the deSolve package in R version 4.1.1 (R Core Team; <https://www.r-project.org/>). To keep it simple, the population size of Ghana, N, was set to 30,800,000. We also assumed that for the base case scenario, at the beginning of the simulation, I =1, A=0, P=0, D=0, and V=0. We accounted for the age-specific seroprevalence of SARS-CoV-2 using estimates from Quarshie and colleagues in August 2020 (29). We, therefore, assumed that 17.5% of persons below 25 years, 43.6% of those between 25-64 years, and 18% of 65+ persons had been infected at the beginning of the simulation. These individuals were in the recovery compartment at the beginning of the



simulation. The model was run for 500 days to allow enough time for the first wave of the epidemic to die out and observe when the second wave began to emerge.

## Outcomes

The cumulative number of infections and deaths averted in the general population was estimated and compared for each scenario. Furthermore, the percent of the population who were symptomatic at the peak, ever infected (cumulative infections), and cumulative deaths were assessed. The percentage of cumulative infection could exceed 100% because as immunity waned, individuals would become susceptible again to repeated infections.

## R code

The R code used for simulation in this study is provided in Appendix 2.

**Appendix 1 Table 1:** Daily vaccination rates for vaccinating 1 million people in 3 months and 6 months using an age-stratified model

Scenario	Fraction of total population	Number in each subgroup	1 million people can be vaccinated, % of the subpopulation vaccinated	The daily vaccination rate for a campaign of 3 m	The daily vaccination rate for a campaign of 6 m
Only ≥65 y	0.0444	1,367,520	73.1%	0.00812	0.00406
25–64 y	0.3948	12,159,840	8.2%	0.00091	0.00046
<25 y	0.5608	17,272,640	5.8%	0.00064	0.00032
<65 y	0.9556	29,432,480	3.4%	0.00038	0.00019
Same vaccination rate	1	30,800,000	3.2%	0.00036	0.00018

**Appendix 1 Table 2:** Daily vaccination rates for vaccinating 500,000 people in 3 months and 6 months using an age-stratified model

Scenario	Fraction of total population	Number in each subgroup	500,000 people can be vaccinated, % of the subpopulation vaccinated	The daily vaccination rate for a campaign of 3 m	The daily vaccination rate for a campaign of 6 m
Only ≥65 y	0.0444	1,367,520	36.6%	0.00406	0.00203
25–64 y	0.3948	12,159,840	4.1%	0.00046	0.00023
<25 y	0.5608	17,272,640	2.9%	0.00032	0.00016
<65 y	0.9556	29,432,480	1.7%	0.00019	0.00009
Same vaccination rate	1	30,800,000	1.6%	0.00018	0.00009

**Appendix 1 Table 3:** Daily vaccination rates for vaccinating two million people in three months and six months using an age-stratified model

Scenario	Fraction of total population	Number in each subgroup	2 million people can be vaccinated, % of the subpopulation vaccinated	The daily vaccination rate for a campaign of 3 m	The daily vaccination rate for a campaign of 6 m
Only ≥65 y	0.0444	1,367,520	146.3%	0.01625	0.00812
25–64 y	0.3948	12,159,840	16.4%	0.00183	0.00091
<25 y	0.5608	17,272,640	11.6%	0.00129	0.00064
<65 y	0.9556	29,432,480	6.8%	0.00075	0.00038
Same vaccination rate	1	30,800,000	6.5%	0.00072	0.00036

**Appendix 1 Table 4:** Sensitivity analysis of outcomes in the total population under various vaccination scenarios using the main matrix for the delta variant\*

Vaccine prioritization, y	500,000 people were vaccinated in 3 m, %	500,000 people were vaccinated in 6 m, %	1 million people were vaccinated in 3 m, %	1 million people were vaccinated in 6 m, %	2 million people were vaccinated in 3 m, %	2 million people were vaccinated in 6 m, %
<b>Symptomatic infections at peak</b>						
Only ≥65	10.25	10.27	10.22	10.25	10.18	10.22
25–64	10.18	10.24	10.08	10.18	9.89	10.08
<25	10.14	10.21	9.99	10.14	9.69	9.99
<65	10.15	10.23	10.02	10.15	9.77	10.02
Same vaccination rate	10.16	10.22	10.03	10.16	9.78	10.03
<b>Cumulative infections</b>						
Only ≥65	229.50	230.26	228.43	229.50	227.20	228.43
25–64	229.07	230.15	227.00	229.07	222.89	227.00
<25	228.77	230.00	226.32	228.77	221.41	226.32
<65	228.87	230.11	226.50	228.87	221.90	226.50
Same vaccination rate	228.89	230.07	226.55	228.89	221.89	226.55
<b>Deaths</b>						
Only ≥65	0.26	0.27	0.25	0.26	0.23	0.25
25–64	0.28	0.28	0.27	0.28	0.27	0.27
<25	0.28	0.28	0.28	0.28	0.27	0.28
<65	0.28	0.28	0.27	0.28	0.27	0.27
Same vaccination rate	0.28	0.28	0.27	0.28	0.27	0.27

\*If there were no vaccination, 10.29% of the population would be symptomatic at the epidemic peak, there would be a total of 231.24% cumulative incidence, and 0.28% of the population would die of COVID-19.

**Appendix 1 Table 5:** Sensitivity analysis of outcomes in the total population under various vaccination scenarios using the second matrix for the Delta variant\*

Vaccine prioritization, y	500,000 people were vaccinated in 3 m, %	500,000 people were vaccinated in 6 m, %	1 million people were vaccinated in 3 m, %	1 million people were vaccinated in 6 m, %	2 million people were vaccinated in 3 m, %	2 million people were vaccinated in 6 m, %
<b>Symptomatic infections at peak</b>						
Only ≥65	10.04	10.09	9.96	10.04	9.85	9.96
25–64	10.01	10.08	9.89	10.01	9.66	9.89
<25	10.01	10.08	9.89	10.01	9.66	9.89
<65	10.01	10.08	9.89	10.01	9.64	9.89
Same vaccination rate	10.01	10.08	9.89	10.01	9.64	9.89
<b>Cumulative infections</b>						
Only ≥65	235.15	236.74	232.82	235.15	230.15	232.81
25–64	236.48	237.60	234.30	236.48	229.96	234.30
<25	236.57	237.65	234.44	236.57	230.18	234.44
<65	236.51	237.67	234.29	236.51	229.99	234.29
Same vaccination rate	236.43	237.58	234.13	236.43	229.52	234.13
<b>Deaths</b>						
Only ≥65	0.28	0.30	0.26	0.28	0.24	0.26
25–64	0.31	0.31	0.31	0.31	0.30	0.31
<25	0.31	0.31	0.31	0.31	0.31	0.31
<65	0.31	0.31	0.31	0.31	0.30	0.31
Same vaccination rate	0.31	0.31	0.31	0.31	0.30	0.31

\*If there were no vaccination, 10.14% of the population would be symptomatic at the epidemic peak, there would be a total of 238.73% cumulative incidence, and 0.31% of the population would die of COVID-19.

## References

1. Liu R, Leung RK, Chen T, Zhang X, Chen F, Chen S, et al. The Effectiveness of Age-Specific Isolation Policies on Epidemics of Influenza A (H1N1) in a Large City in Central South China. *PLoS One*. 2015;10:e0132588. [PubMed https://doi.org/10.1371/journal.pone.0132588](https://doi.org/10.1371/journal.pone.0132588)
2. Zhao Z-Y, Zhu Y-Z, Xu J-W, Hu S-X, Hu Q-Q, Lei Z, et al. A five-compartment model of age-specific transmissibility of SARS-CoV-2. *Infectious Diseases of Poverty*. 2020;9(1):117.
3. Abbasi Z, Zamani I, Mehra AHA, Shafieirad M, Ibeas A. Optimal Control Design of Impulsive SQEIAR Epidemic Models with Application to COVID-19. *Chaos, Solitons & Fractals*. 2020;139:110054.
4. Liu Z, Magal P, Seydi O, Webb G. A COVID-19 epidemic model with latency period. *Infect Dis Model*. 2020;5:323–37. [PubMed https://doi.org/10.1016/j.idm.2020.03.003](https://doi.org/10.1016/j.idm.2020.03.003)
5. Chen M, Li M, Hao Y, Liu Z, Hu L, Wang L. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. *Inf Fusion*. 2020;64:252–8. [PubMed https://doi.org/10.1016/j.inffus.2020.08.002](https://doi.org/10.1016/j.inffus.2020.08.002)
6. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med*. 2020;17:e1003346. [PubMed https://doi.org/10.1371/journal.pmed.1003346](https://doi.org/10.1371/journal.pmed.1003346)

7. Tindale LC, Stockdale JE, Coombe M, Garlock E, Lau WYV, Saraswat M, et al. Evidence for transmission of COVID-19 prior to symptom onset. *eLife*. 9:e57149  
<https://doi.org/10.7554/eLife.57149>
8. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy*. 2020;75:1742–52. [PubMed](#)  
<https://doi.org/10.1111/all.14309>
9. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. *BMJ Open*. 2020;10:e039856. [PubMed](#)  
<https://doi.org/10.1136/bmjopen-2020-039856>
10. Thiruvengadam G, Ramanujam R, Marappa L. Modeling the recovery time of patients with coronavirus disease 2019 using an accelerated failure time model. *J Int Med Res*. 2021;49:3000605211040263. [PubMed](#) <https://doi.org/10.1177/03000605211040263>
11. Xing Y-H, Ni W, Wu Q, Li W-J, Li G-J, Wang W-D, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. *J Microbiol Immunol Infect*. 2020;53:473–80. [PubMed](#) <https://doi.org/10.1016/j.jmii.2020.03.021>
12. University of British Columbia Department of Zoology. COVID-19 Models Lecture. 2020 [cited November 15, 2020]; Available from:  
[https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID\\_Models.pdf](https://www.zoology.ubc.ca/~bio301/Bio301/Lectures/Lecture1/COVID_Models.pdf)
13. Centers for Disease Control and Prevention. Pandemic Planning Scenarios. 2020 [cited November 12, 2020]; Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>
14. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet*. 2021;397:72–4. [PubMed](#) [https://doi.org/10.1016/S0140-6736\(20\)32623-4](https://doi.org/10.1016/S0140-6736(20)32623-4)
15. Good MF, Hawkes MT. The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. *MBio*. 2020;11:e02617-20. [PubMed](#) <https://doi.org/10.1128/mBio.02617-20>
16. Keeling MJ, White PJ. Targeting vaccination against novel infections: risk, age and spatial structure for pandemic influenza in Great Britain. *J R Soc Interface*. 2011;8:661–70. [PubMed](#)  
<https://doi.org/10.1098/rsif.2010.0474>


17. Ashinyo ME, Duti V, Dubik SD, Amegah KE, Kutsoati S, Oduro-Mensah E, et al.. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. *Pan Afr Med J.* 2020;37(Suppl 1):9. [PubMed](#)  
<https://doi.org/10.11604/pamj.supp.2020.37.1.25718>
18. Central Intelligence Agency. The world factbook. 2022 [cited December 4, 2022].  
<https://www.cia.gov/the-world-factbook/>
19. Anderson RM, May RM. *Infectious diseases of humans: dynamics and control*: Oxford university press; 1992.
20. Towers S, Feng Z. Social contact patterns and control strategies for influenza in the elderly. *Math Biosci.* 2012;240:241–9. [PubMed](#) <https://doi.org/10.1016/j.mbs.2012.07.007>
21. Towers S. SIR infectious disease model with age classes. 2012 [cited September 15, 2021].  
<http://sherrytowers.com/2012/12/11/sir-model-with-age-classes/>
22. le Polain de Waroux O, Cohuet S, Ndazima D, Kucharski AJ, Juan-Giner A, Flasche S, et al. Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. *BMC Infect Dis.* 2018;18(1):172.
23. Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. *PLoS One.* 2014;9:e104786. [PubMed](#) <https://doi.org/10.1371/journal.pone.0104786>
24. Melegaro A, Jit M, Gay N, Zagheni E, Edmunds WJ. What types of contacts are important for the spread of infections?: using contact survey data to explore European mixing patterns. *Epidemics.* 2011;3:143–51. [PubMed](#) <https://doi.org/10.1016/j.epidem.2011.04.001>
25. Trentini F, Guzzetta G, Galli M, Zardini A, Manenti F, Putoto G, et al. Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia. *BMC Med.* 2021;19:89. [PubMed](#)  
<https://doi.org/10.1186/s12916-021-01967-w>
26. Melegaro A, Del Fava E, Poletti P, Merler S, Nyamukapa C, Williams J, et al. Social contact structures and time use patterns in the Manicaland Province of Zimbabwe. *PLoS One.* 2017;12:e0170459. [PubMed](#) <https://doi.org/10.1371/journal.pone.0170459>
27. Kenu E, Odikro MA, Malm KL, Asiedu-Bekoe F, Noora CL, Frimpong JA, et al. Epidemiology of COVID-19 outbreak in Ghana, 2020. *Ghana Med J.* 2020;54(Suppl):5–15. [PubMed](#)  
<https://doi.org/10.4314/gmj.v54i4s.3>

28. Lawal Y. Africa's low COVID-19 mortality rate: A paradox? *Int J Infect Dis.* 2021;102:118–22.

[PubMed https://doi.org/10.1016/j.ijid.2020.10.038](https://doi.org/10.1016/j.ijid.2020.10.038)

29. Quashie PK, Mutungi JK, Dzabeng F, Oduro-Mensah D, Oporum PC, Tapela K, et al. Trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence in selected regions across Ghana. *Wellcome Open Res.* 2021; 6:173.

<https://doi.org/10.12688/wellcomeopenres.16890.1>



**Appendix 1 Figure:** The Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated (SEPIARD-V) model represents SARS-CoV-2 transmission and COVID-19 disease progress and the vaccination against COVID-19. Note: Age-stratification is not represented in this flow diagram.

# Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana

## Appendix 2

Coding in R for age-stratified model to assess health outcomes of COVID-19 vaccination strategies, Ghana.

First we clear the workspace to get rid of leftover variables.

```
rm(list=ls())
```

Next we clear all graphic windows.

```
graphics.off();
```

We load packages that are required for the R simulation.

```
pacman::p_load(ggplot2,  
               deSolve,  
               reshape2)
```

We set a seed so that the same simulation outputs can be obtained when simulations are repeated.

```
set.seed(1234)
```

## SEAPIRD-V model

- S refers to susceptible individuals.
- E refers to exposed individuals who are in the latent state.
- A refers to asymptomatic individuals: A percentage of the infected population makes transitions into the asymptomatic state. They are infectious.
- P refers to pre-symptomatic individuals: A percentage of the infected population makes transitions into the pre-symptomatic state. They are infectious.
- I refers to symptomatic individuals. They are infectious.
- R refers to recovered: Asymptomatic and Symptomatic individuals enter the recovery state.
- D refers to symptomatic individuals who died from COVID-19.

- V refers to individuals who become immune from COVID-19 infection after receiving two doses of the AstraZeneca vaccine.

## Parameter definitions

Parameters:

- c: transition rate from presymptomatic to symptomatic=  $1/(\text{incubation period} - \text{latency period})$
- beta: transmission coefficient
- q: recovery rate for asymptomatic individuals
- delta: probability that exposed persons become presymptomatically infected
- f: the inverse of the duration of individuals being symptomatic (equals to the recovery rate for symptomatic individuals)
- u: relative transmissibility of asymptomatic individuals
- r: relative transmissibility of pre-symptomatic individuals
- sigma: vaccine efficacy
- v: vaccination rate
- chi: waning immunity of vaccinated individuals
- Ro: reproduction number
- z: age-specific case fatality ratio

In this study, two strains of COVID-19 were assessed by varying the reproduction numbers and vaccine efficacy with the values below

```
#values for R and vaccine efficacy for each strain
#initial
#Ro      = 3.13
#sigma   = 0.745

#delta variant
#Ro      = 5.35
#sigma   = 0.67
```

An age-specific case fatality ratio was calculated: We assumed 9% of deaths in the population occurred in children, 51% between 25 and 64 years, and 40% of deaths in the elderly. These translated into the following CFR: <25 yr = 0.002; 25-64 yr = 0.005; 65+ yr = 0.048. See Appendix 1 for more details.

```
z= c(0.002, 0.005, 0.048)
```

We created a function for the age-stratified model with 9 compartments with the set of ordinary differential equations that defines the model.

```
agestratified <- function(time,state,parameters){
  ncompartment = 9 #number of compartments in the model
  nage = length (state)/ncompartment
  S     = as.matrix(state[1:nage])
```



```

E = as.matrix(state[(nage+1):(2*nage)])
A = as.matrix(state[(2*nage+1):(3*nage)])
P = as.matrix(state[(3*nage+1):(4*nage)])
I = as.matrix(state[(4*nage+1):(5*nage)])
R = as.matrix(state[(5*nage+1):(6*nage)])
D = as.matrix(state[(6*nage+1):(7*nage)])
V = as.matrix(state[(7*nage+1):(8*nage)])
L = as.matrix(state[(8*nage+1):(9*nage)])

I[I<0] = 0

with(as.list(parameters),{
  N = S+E+P+I+A+R+D+V
  lambda = (I+u*A+r*P)/N
  dS = -beta*as.matrix(S)*(as.matrix(C)%*(as.matrix(lambda)))+
    w*as.matrix(R)- v*sigma*as.matrix(S) + chi*as.matrix(V)
  dE = beta*as.matrix(S)*(as.matrix(C)%*(as.matrix(lambda)))- k*as.matrix(E)
  dA = (1-delta)*k*as.matrix(E)-q*as.matrix(A)
  dP = delta*k*as.matrix(E)-c*as.matrix(P)
  dI = c*as.matrix(P)-f*as.matrix(I)
  dR = (1-z)*f*as.matrix(I)+q*as.matrix(A)-w*as.matrix(R)
  dD = z*f*as.matrix(I)
  dV = v*sigma*as.matrix(S)-chi*as.matrix(V)
  dL = k*as.matrix(E)

  out=c(dS, dE, dA, dP, dI, dR, dD, dV, dL)
  list (out)
}
)
}

```

We determined the number of persons in each age group assuming a population size of 30,800,000.

```

lcalculate_transmission_probability = 1
popul= 30800000
g= c(0.5608, 0.3948, 0.0444) #3 age classes explained above
N= popul*g #number in each age class
nage = length (g)

```

### Setting initial state for compartments

We assumed a % of each subpopulation was already infected, hence they were in the recovered compartment at the beginning of the simulation.

```

I_0 = rep (1, nage) #One infectious person in each age group
S_0 = N-R_0 #susceptible individuals at the beginning of simulation in each class
E_0 = rep (0, nage)
A_0 = rep (0, nage)

```

```

P_0 = rep (0, nage)
R_0 = N*(c(0.175,
          0.436,
          0.180))#accounting for initially infected in each class
D_0 = rep (0, nage)
V_0 = rep (0, nage)
L_0 = rep (0, nage)

```

Two contact matrices were used in the study a) the first matrix is defined as the “main matrix”.

```

C = matrix(0, nrow=nage, ncol=nage)
C[1,1] = 23.58
C[1,2] = 9.31
C[1,3] = 0.87
C[2,1] = 13.01
C[2,2] = 15.05
C[2,3] = 1.53
C[3,1] = 2.29
C[3,2] = 2.44
C[3,3] = 0.54

```

b) The other matrix is defined as “second matrix”

```

#C = matrix(0, nrow=nage, ncol=nage)
#C[1,1] = 8.2
#C[1,2] = 5
#C[1,3] = 1
#C[2,1] = 2
#C[2,2] = 7.8
#C[2,3] = 2.8
#C[3,1] = 0.1
#C[3,2] = 2.2
#C[3,3] = 1.60

```

We set the parameter values used for calculating beta.

```

delta = 0.3
k      = 0.54
c      = 0.344
q      = 0.14
f      = 0.064
u      = 0.75
r      = 0.75

```

We defined the formulae for calculating the beta using the reproduction number from the largest eigenvalue.

```

if (lcalculate_transmission_probability==1){
  M      = C
  M[1,1] = C[1,1]*g[1]/g[1]
  M[1,2] = C[1,2]*g[1]/g[2]

```

```

M[1,3] = C[1,3]*g[1]/g[3]
M[2,1] = C[2,1]*g[2]/g[1]
M[2,2] = C[2,2]*g[2]/g[2]
M[2,3] = C[2,3]*g[2]/g[3]
M[3,1] = C[3,1]*g[3]/g[1]
M[3,2] = C[3,2]*g[3]/g[2]
M[3,3] = C[3,3]*g[3]/g[3]
eig = eigen(M)
# Re() function extracts the real part of a complex number, in the event th
at the eigenvalue is a complex number.
Beta = ((Ro*c*f*q)/((delta*r*f*q)+(delta*c*q)+((1-delta)*u*c*f)))/max(Re(ei
g$values))
beta=Beta
}else{
beta = 0.34
}

```

We defined the initial state conditions.

```

initial_state = c(S= S_0,
                 E= E_0,
                 A= A_0,
                 P= P_0,
                 I= I_0,
                 R= R_0,
                 D= D_0,
                 V= V_0,
                 L= L_0)

```

We created a vector for the parameters for initializing our model.

```

parameters = c( delta = 0.3,
                 k     = 0.54,
                 c     = 0.344,
                 beta  = Beta,
                 q     = 0.14,
                 v     = 0.0003519,
                 f     = 0.064,
                 u     = 0.75,
                 r     = 0.75,
                 w     = 0.0055,
                 chi   = 0.0027,
                 sigma = 0.745,
                 z     = z)

```

The model was simulated for 500 days to allow enough time for the second wave to emerge.

```
time = seq (0, 500, 1)
```

We solved the differential equations using the `lsoda()` function in the `deSolve` package:

```
teta<-as.data.frame(l soda(initial_state,
                           time,
                           agestratified,
                           parameters))
```

We converted the data into a long format using the melt() function in the reshape2 package:

```
out_long=melt(teta,
              id="time")
tail (teta)
```

## Scenario analysis of the impact of vaccine optimization strategies

Part 1: use v rates accounting for vaccine supplies only one million people can get vaccinated in 3 months

```
#v= c(0,      0,      0.00812)  #only elderly vaccinated
#v= c(0,      0.00091,  0)      #adults vaccinated
#v= c(0.00064,  0,      0)      #younger population vaccinated
#v= c(0.00038,  0.00038,  0)    #adults and younger vaccinated
#v= c(0,      0,      0)        #no vaccination
#v= c(0.00036,  0.00036,  0.00036) #same vaccination rate
```

Part 2: only one million people can get vaccinated in 6 months

```
#v= c(0,      0,      0.00406)  #only elderly vaccinated
#v= c(0,      0.00046,  0)      #adults vaccinated
#v= c(0.00032,  0,      0)      #younger population vaccinated
#v= c(0.00019,  0.00019,  0)    #adults and younger vaccinated
#v= c(0,      0,      0)        #no vaccination
#v= c(0.00018,  0.00018,  0.00018) #same vaccination rate
```

Part 3: only 500,000 get vaccinated in 3 months

```
#v= c(0,      0,      0.00406)  #only elderly vaccinated
#v= c(0,      0.00046,  0)      #adults vaccinated
#v= c(0.00032,  0,      0)      #younger population vaccinated
#v= c(0.00019,  0.00019,  0)    #adults and younger vaccinated
#v= c(0,      0,      0)        #no vaccination
#v= c(0.00018,  0.00018,  0.00018) #same vaccination rate
```

Part 4: only 500,000 get vaccinated in 6 months

```
#v= c(0,      0,      0.00203)  #only elderly vaccinated
#v= c(0,      0.00023,  0)      #adults vaccinated
#v= c(0.00016,  0,      0)      #younger population vaccinated
#v= c(0.00009,  0.00009,  0)    #adults and younger vaccinated
#v= c(0,      0,      0)        #no vaccination
#v= c(0.00009,  0.00009,  0.00009) #same vaccination rate
```

Part 5: only 2,000,000 get vaccinated in 3 months

```
#v= c(0, 0, 0.01625) #only elderly vaccinated
#v= c(0, 0.00183, 0) #adults vaccinated
#v= c(0.00129, 0, 0) #younger population vaccinated
#v= c(0.00075, 0.00075, 0) #adults and younger vaccinated
#v= c(0, 0, 0) #no vaccination
#v= c(0.00072, 0.00072, 0.00072) #same vaccination rate
```

Part 6: only 2,000,000 get vaccinated in 6 months

```
#v= c(0, 0, 0.00812) #only elderly vaccinated
#v= c(0, 0.00091, 0) #adults vaccinated
#v= c(0.00064, 0, 0) #younger population vaccinated
#v= c(0.00038, 0.00038, 0) #adults and younger vaccinated
#v= c(0, 0, 0) #no vaccination
#v= c(0.00036, 0.00036, 0.00036) #same vaccination rate
```

We defined parameter values for the simulation.

```
parameters = c( delta = 0.3,
                 k     = 0.54,
                 c     = 0.344,
                 beta  = Beta,
                 q     = 0.14,
                 v     = v,
                 f     = 0.064,
                 u     = 0.75,
                 r     = 0.75,
                 w     = 0.0055,
                 chi   = 0.0027,
                 sigma = sigma,
                 z     = z)
```

We solved the differential equations as:

```
teta<-as.data.frame(lsoda(initial_state,
                          time,
                          agestratified,
                          parameters))
out_long=melt(teta,id="time")
tail (teta)
```

## Calculating the percentage of population with each outcome under the various vaccination scenarios

The percentage of the population who are symptomatic at the peak:

```
cat("The % of the population who are symptomatic at the peak is ",(max(teta$I1+teta$I2+teta$I3)/popul)*100,"\n")
```

The % of population ever infected:

```
cat("The % of the population ever infected is ",(max(teta$L1+teta$L2+teta$L3)/popul)*100,"\n")
```

The % of population who died:

```
cat("The % of the population who died is ",(max(teta$D1+teta$D2+teta$D3)/popul)*100,"\n")
```